Last reviewed · How we verify
Autologous Cellular Therapy with PRP-PC — Competitive Intelligence Brief
phase 2
Regenerative Medicine
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous Cellular Therapy with PRP-PC (Autologous Cellular Therapy with PRP-PC) — H-CYTE. Autologous Cellular Therapy with PRP-PC involves using a patient's own cells, combined with platelet-rich plasma and platelet concentrate, to stimulate healing and tissue repair.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous Cellular Therapy with PRP-PC TARGET | Autologous Cellular Therapy with PRP-PC | H-CYTE | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous Cellular Therapy with PRP-PC CI watch — RSS
- Autologous Cellular Therapy with PRP-PC CI watch — Atom
- Autologous Cellular Therapy with PRP-PC CI watch — JSON
- Autologous Cellular Therapy with PRP-PC alone — RSS
Cite this brief
Drug Landscape (2026). Autologous Cellular Therapy with PRP-PC — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-cellular-therapy-with-prp-pc. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab